Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Neal Katz

Neal Katz

Director of Solutions Marketing

Connect with Neal Katz on LinkedIn
Website:

About the author: Neal Katz has over 20 years of experience bringing information technology solutions to market. As Senior Manager of Solutions Marketing at Elsevier, Neal has been responsible for assembling information solutions for life science companies, as well as academic and government institutions. He has developed similar solutions and programs at companies like AT&T and Intel.

Posts by Neal Katz

Pharmacovigilance events in different regions cover common concerns

Posted on January 7th, 2016 in Pharmacovigilance

In December, Elsevier sponsored the 11th Annual Pharmacovigilance, Drug Safety and Risk Management conference in Brussels, Belgium and the 2nd Adverse Event Reporting and Safety Strategies Summit in Philadelphia, USA.  (more…)

A New Approach to Drug Analytics

Posted on December 18th, 2015 in Pharma R&D

Technological advances in the retrieval and assessment of pathway and bioactivity data are giving rise to new in silico profiling and modeling methods. (more…)

The Importance of Literature on Medical Device Development and Post Market Surveillance

Posted on November 13th, 2015 in Chemistry

Before the ideation and creation of a novel prototype device — or the establishment of a new purpose for an existing one — medical device manufacturers must be confident that the device will serve a real need in the market. They must also establish that the device has unique value and will be safe and effective. (more…)

Best Practices for Post-Market Surveillance Processes

Posted on November 13th, 2015 in Pharmacovigilance

Donna Sees, an Information Consultant with PharmIntell Consulting, has been a librarian in the medical field for more than 10 years. In this article, she discusses post-market surveillance processes and best practices for medical device companies.

Learn how PharmIntell Consulting took advantage of QUOSA.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5